daratumumab
Daratumumab Delays Transition From Smoldering to Active Multiple Myeloma
In a phase 3 trial, the anti-38 monoclonal antibody Darzalex substantially delayed or prevented transformation of ...
FEBRUARY 20, 2025
Darzalex Plus VTd Approved for Newly Diagnosed HCT-Eligible Multiple Myeloma
The FDA approved daratumumab (Darzalex, Janssen) in combination with VTd (bortezomib, thalidomide, dexamethasone) ...
SEPTEMBER 30, 2019
FDA Approves Split-Dose Regimen for Darzalex
Splitting the first dose of daratumumab over two consecutive days effectively reduced the duration of the first ...
FEBRUARY 12, 2019
Adding Daratumumab Extends PFS in Transplant-Ineligible MM
When added to the standard combination of lenalidomide and dexamethasone in previously untreated MM patients ...
FEBRUARY 8, 2019
Darzalex Approved to Treat Newly Diagnosed MM Patients
The FDA approved daratumumab (Darzalex, Janssen) in combination with VMP (bortezomib [Velcade, Millennium], ...
MAY 9, 2018
FDA Gives New Indication for Darzalex With 2 Standard Treatments for MM
Daratumumab induces tumor cell death through multiple immune-mediated mechanisms of action, including ...
NOVEMBER 22, 2016
